Skip to main content

Table 2 Final model for the stepwise Cox hazard model analysis showing Hazard Ratio (with relative confidence intervals and p-values) for relapsing after the increase of IFNB dose.

From: Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

 

HR

95% C.I.

p-value

Male gender

0.68

0.39 - 1.16

0.1

Age at switch (each year)

0.94

0.91 - 0.97

<0.001

No. of relapses occurred during the low-dose IFNB regimen

   

   0 (*)

Ref.

-

-

   1

3.56

1.34 - 8.42

0.01

   ≥ 2

7.89

3.10 - 19.85

<0.001

IFNB type (Betaferon or Rebif 44)

1.14

0.52 - 2.51

0.7

  1. IFNB: Interferon Beta; EDSS: Expanded Disability Status Scale
  2. (*) this value refers to patients switched only on the basis of an active MRI scan